A PASSPORT
To Understanding Treatment With LUTATHERA

Keep track of your progress, appointments, and questions for your health care professional

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

IMPORTANT SAFETY INFORMATION

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop your treatment. You should always follow your health care provider's instructions. Safety considerations include:

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation, which can contribute to your long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer. The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your health care provider.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Hi, I'm Luke. I'm here to guide you through your treatment journey with LUTATHERA.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

Table of Contents

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

What Is LUTATHERA?

LUTATHERA is a prescription treatment for adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin.

LUTATHERA is given as an intravenous (IV) infusion.

- A full course of therapy consists of 4 doses of LUTATHERA. These doses will be 8 weeks apart. You and your health care professional will decide how many doses are right for you, as well as the time between each dose

Typical Treatment Regimen With LUTATHERA



Long-acting somatostatin analogs, also called SSAs, should be discontinued for at least 4 weeks prior to initiating LUTATHERA.

Short-acting octreotide may be given for symptomatic management during treatment with LUTATHERA, but must be withheld for at least 24 hours before each dose of LUTATHERA.

[a]During treatment with LUTATHERA, 30 mg of long-acting octreotide will be administered intramuscularly (IM) between 4 to 24 hours after each dose of LUTATHERA.

[b]You will continue to receive 30 mg of long-acting octreotide IM every 4 weeks for up to 18 months after starting treatment with LUTATHERA or until the time when your cancer may spread, grow, or get worse, or until your health care professional tells you to stop taking octreotide.

Talk to your health care professional if you have any questions about your treatment regimen with LUTATHERA.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

How Does LUTATHERA Work?

LUTATHERA is the first and only approved radioligand therapy (RLT) for GEP-NETs, a medicine from a class of drugs called peptide receptor radionuclide therapy (PRRT).

- LUTATHERA is believed to work differently from most cancer medicines, with a 2-part approach that specifically targets and enters the cells that have somatostatin receptors, releasing energy in the form of radiation that damages them and nearby cells

In other words, LUTATHERA is a "key" that connects with the "lock" (cells containing somatostatin receptors).

1. Attaches to Target Cells

LUTATHERA is designed to contain a tumor-targeting part that attaches to cells with somatostatin receptors, including GEP-NET cancer cells.

Once it finds these cells, LUTATHERA is designed to bind to the somatostatin receptors located on the outside of the cells.

2. Enters the Cells



After LUTATHERA binds to the somatostatin receptors, it is designed to enter the cell.



Once inside the cell, LUTATHERA will deliver radiation that causes damage to both the targeted cells with these receptors, as well as neighboring cells.



What are some important things to know about the safety of LUTATHERA? (continued)

- **Bone marrow problems:** Treatment with LUTATHERA increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts. You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia). Speak with your health care provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. Your health care provider may need to adjust or stop your treatment accordingly.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Sharing Your Medical Information

To prepare for your appointment with your health care professional, it may be helpful to use the space below to share your current medicines, and/or those you have taken in the past.

Prescription History and Important Contacts

Prescriptions:

- ☐ **Somatostatin analogs (eg, octreotide, lanreotide)**
- ☐ **Corticosteroids (eg, hydrocortisone, dexamethasone)**

Other Prescriptions:

Over-the-Counter Medicines (eg, vitamins, supplements, and herbs):

Previous Medicines:

Health Care Professional (Medical Oncologist): Phone Number:	
Treatment Center for LUTATHERA: Phone Number:	
Emergency Contact and Relationship: Phone Number:	

Providing your health care professional with a complete medical history is important while receiving treatment with LUTATHERA.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

Communicating With Your Health Care Professional

It's important to tell your health care professional everything about your disease and health status.

Health Information You May Want to Discuss

- ☑ Any medical conditions you may have
- ☑ Symptoms you may have
- ☑ Any changes in your daily habits
- ☑ If you have trouble controlling when you urinate or have a bowel movement
- ☑ All the medicines you are taking, including over-the-counter medicines
- ☑ If you are trying to get pregnant, if you are already pregnant, or if you are breastfeeding

Make sure to let your health care professional know if you are taking a type of medicine called a somatostatin analog, also called an SSA, and/or glucocorticoids. If you are taking either, you might have to stop or change your treatment before and while receiving LUTATHERA.

- If you are a female who is able to get pregnant, use effective contraception during treatment with LUTATHERA and for 7 months after the last dose
- If you are a male with a female partner who is able to get pregnant, use effective contraception during treatment with LUTATHERA and for 4 months after the last dose
- Women should not breastfeed during treatment with LUTATHERA and for 2.5 months after the last dose

Having open and regular conversations with your health care professional is important prior to starting and during treatment with LUTATHERA.

What are some important things to know about the safety of LUTATHERA? (continued)

- **Secondary bone marrow and blood cancers:** Other serious conditions that you may develop as a direct result of treatment with LUTATHERA include blood and bone marrow disorders known as secondary myelodysplastic syndrome and cancer known as acute leukemia. Your health care provider will routinely check your blood cell counts and tell you if they are too low or too high.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Keeping Track of Your Questions and Answers

It may be helpful to write down any questions you may have for your health care professional in the space below and discuss them at your next appointment. We have included a couple of sample questions to get you started.

Write Down Any Questions You May Have

In which treatment center will I receive LUTATHERA? Will I receive octreotide at the same treatment center?

Write Down Responses You Want to Remember

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

Your Treatment Journey Before Starting LUTATHERA

After your health care professional has prescribed LUTATHERA, you will be referred to a treatment site where trained health care professionals will guide you through the process.

1 At Least 4 Weeks Before Starting LUTATHERA

- You will stop receiving a monthly, long-acting SSA, and your health care professional might administer short-acting octreotide as needed to control symptoms

2 Before Starting First Treatment With LUTATHERA

- An imaging test will be performed to localize the tumor. Your health care professional may also perform some blood tests and other tests to evaluate your kidneys, liver, and blood
- Pregnancy status will be verified before starting LUTATHERA, because it has the potential to cause fetal harm

3 Up to 24 Hours Before Starting LUTATHERA

- Your health care professional might administer short-acting octreotide as needed for symptom management, but will discontinue at least 24 hours before your treatment with LUTATHERA

What are some important things to know about the safety of LUTATHERA? (continued)

- **Kidney problems:** Treatment with LUTATHERA will expose your kidneys to radiation and may impair their ability to work as normal. You may be at an increased risk for kidney problems after LUTATHERA treatment if you already have kidney impairment before treatment. In some cases, patients have experienced kidney failure after treatment with LUTATHERA. Your health care provider will provide you with an amino acid solution before, during, and after LUTATHERA to help protect your kidneys. You should stay well hydrated before, on the day of, and on the day after your treatment. You should urinate frequently before, on the day of, and on the day after administration of LUTATHERA. Your doctor will monitor your kidney function and may withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

Your Treatment Journey While Receiving LUTATHERA

4 Day of Treatment With LUTATHERA

- You will go to the treatment center recommended by your health care professional to receive LUTATHERA. This is usually done in the nuclear medicine department
- **Before you are given LUTATHERA:** You will be given a medicine that is intended to help with vomiting or an upset stomach that you may experience because of the treatment
- **30 minutes before you are given LUTATHERA:** You will be given an amino acid solution through an IV infusion to help protect your kidneys. This infusion will last for the duration of your treatment with LUTATHERA and for at least 3 hours after it has been completed
- **The infusion of LUTATHERA:** It will take approximately 30 to 40 minutes and is given as an IV infusion

5 Subsequent Treatments With LUTATHERA

- You may receive LUTATHERA up to 3 more times after your first infusion. These doses will be between 8 and 16 weeks apart, depending on how you may tolerate the medicine
- You and your health care professional will decide how many doses and how long between each dose is right for you
  - Tests evaluating your liver, kidneys, and blood may be conducted again

6 After Last Treatment With LUTATHERA

- After your last dose of LUTATHERA, tests evaluating your liver, kidneys, and blood may be conducted again
- You may continue receiving 30 mg of long-acting octreotide every 4 weeks for 18 months after starting treatment with LUTATHERA, depending on your health care professional's instructions, or until your cancer starts to spread or get worse

See pages 12 to 18 and the Summary of Important Information on pages 22 and 23 for information and helpful considerations on radiation exposure, safety, and managing side effects.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Helpful Considerations While on Treatment With LUTATHERA

Minimizing radiation exposure to those around you

Your health care professional will provide you with information to help minimize radiation exposure to those around you while you are on treatment with LUTATHERA. Here are some other considerations to keep in mind. Guidelines for minimizing radiation exposure may vary depending on the health care professional and/or facility.

Using the toilet

- For a few days after your treatment with LUTATHERA, use the toilet in a seated position, even for men, and use toilet paper each time
- For a few days after you receive LUTATHERA, flush toilet paper and/or wipes down the toilet and flush twice
- Wash your hands every time you use the toilet

Showering

- Daily showering is recommended for at least the first few days after receiving LUTATHERA

Your caretaker

- If a caretaker helps you in the bathroom, they should wear disposable gloves for the first few days after you are given LUTATHERA

It's important to follow your health care professional's instructions to help minimize radiation exposure to others.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

After Each Treatment With LUTATHERA

At the treatment center

LUTATHERA is a nuclear medicine therapy. While you are taking LUTATHERA, you will be kept away from other patients in the hospital to limit their exposure. Your family members and caregivers might be allowed to stay with you during your treatment, but they may be asked to leave for 30 to 40 minutes while LUTATHERA is being given.

You may also want to bring a book to read or your electronic device to listen to music or watch a movie.

After receiving LUTATHERA

Your nuclear medicine doctor will provide further instructions to help minimize radiation exposure to others. You should always follow your health care professional's instructions.

You should drink plenty of fluids on the day before, on the day of, and on the day after you receive LUTATHERA. Generally, the more you urinate, the faster you will get rid of the excess radiation from your body.

What are some important things to know about the safety of LUTATHERA? (continued)

- **Liver problems:** In clinical studies of LUTATHERA, less than 1% of patients were reported to have tumor bleeding (hemorrhage), swelling (edema), or tissue damage (necrosis) to the liver. If you have tumors in your liver, you may be more likely to experience these side effects. Tell your health care provider right away if you have any of these signs and symptoms of liver problems: yellowing of the skin or the whites of the eyes (jaundice), unusual darkening of the urine, unusual tiredness, right upper stomach area (abdomen) pain, confusion, and/or swelling of the stomach area (abdomen). Your health care provider will monitor your liver using blood tests and may need to withhold, reduce, or stop your LUTATHERA treatment accordingly.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Treatment Cards for LUTATHERA

Your nuclear medicine doctor may fill out a treatment card for LUTATHERA and give it to you after each treatment dose. This card will list your name, the amount of medicine that you received, and a hospital contact name and phone number. You should keep the card with you after your treatment, especially if you are traveling through an airport.

You may receive a card at each of your four doses. Please refer to the facing page or LUTATHERA.com for extra treatment cards.

Treatment card example

Patient: *John Doe*

Hospital: *My Treatment Center*

City, State: *Hospital City, NY*

24-hour contact name and number at hospital:

Dr Julia Doe, (123) 123-4567

This patient has been administered LUTATHERA

Procedure date and time: *12/12/2023, 12:12 PM*

Activity administered: *7.4 GBq*

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Scan the QR code to get a downloadable/printable version of the Patient Treatment Cards.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

Treatment Cards for LUTATHERA

Patient: ______________________

Hospital: ______________________

City, State: ______________________

24-hour contact name and number at hospital:

____

This patient has been administered LUTATHERA

Procedure date and time: ______________________

Activity administered: ______________________



LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Patient: ______________________

Hospital: ______________________

City, State: ______________________

24-hour contact name and number at hospital:

____

This patient has been administered LUTATHERA

Procedure date and time: ______________________

Activity administered: ______________________



LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Patient: ______________________

Hospital: ______________________

City, State: ______________________

24-hour contact name and number at hospital:

____

This patient has been administered LUTATHERA

Procedure date and time: ______________________

Activity administered: ______________________



LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Patient: ______________________

Hospital: ______________________

City, State: ______________________

24-hour contact name and number at hospital:

____

This patient has been administered LUTATHERA

Procedure date and time: ______________________

Activity administered: ______________________

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Notes: _____

Travel Notes: _____

NOVARTIS

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 Printed in USA 7/23 296340

Notes: _____

Travel Notes: _____

NOVARTIS

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 © 2023 Novartis Printed in USA 7/23 296340

Notes: _____

Travel Notes: _____

NOVARTIS

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 © 2023 Novartis Printed in USA 7/23 296340

Notes: _____

Travel Notes: _____

NOVARTIS

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 © 2023 Novartis Printed in USA 7/23 296340

Keeping Track of Your Treatment Journey

While receiving LUTATHERA, you may have a number of appointments with your health care professional. You can use the area below to keep track of them and how you are feeling to help you remember the information when talking to your health care professional.

What to keep in mind about octreotide

During treatment with LUTATHERA, 30 mg of long-acting octreotide will be administered IM between 4 to 24 hours after each dose of LUTATHERA. Short-acting octreotide may be given for symptomatic management during treatment with LUTATHERA, but must be withheld for at least 24 hours before each dose of LUTATHERA.

- Your health care professional will inform you when and where long-acting octreotide will be administered
- You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088

Dose 1	Appointment Date	Follow-Up Date
How are you feeling?		

Dose 2	Appointment Date	Follow-Up Date
How are you feeling?		

Dose 3	Appointment Date	Follow-Up Date
How are you feeling?		

Dose 4	Appointment Date	Follow-Up Date
How are you feeling?		

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Potential Side Effects

All prescription medicines come with safety considerations. Some considerations you should be aware of before starting LUTATHERA relate to:

- Radiation exposure
- Bone marrow problems
- Secondary bone marrow and blood cancers
- Kidney problems
- Liver problems
- Allergic reactions
- Hormonal gland problems (hormonal crisis)
- Embryo-fetal toxicity
- Infertility

What side effects could I experience with LUTATHERA?

LUTATHERA may cause side effects. Some of these side effects can be serious, and your health care professional may need to adjust or stop your treatment if you experience any of these. You should always follow the instructions from your health care professional.

In clinical trials, the most common grade 3/4 (severe) adverse reactions occurring with a greater frequency among patients receiving LUTATHERA included:

- Decreased blood cell counts
- Increased liver enzymes
- Vomiting
- Nausea
- Increased blood glucose levels
- Decreased blood potassium levels

Talk to your health care professional if you experience any side effects. There are other possible side effects of LUTATHERA. For more information, and to learn more about LUTATHERA, talk to your health care professional.

Please see additional warnings in this brochure and in the full Prescribing Information regarding pregnancy, breastfeeding, and use of birth control.

Talk to your health care professional if you have any of these side effects or experience any other side effects associated with LUTATHERA.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

Find Support Organizations for GEP-NETs

A support network of family, friends, and caregivers may help you through your treatment journey. In addition, support communities can provide you with information you or your caregiver may find helpful.

Carcinoid Cancer Foundation (CCF)
118 N. Bedford Road, Suite 100
Mt. Kisco, NY 10549
1-914-683-1001
www.carcinoid.org

Healing NET Foundation
415 Spence Lane
Nashville, TN 37210
1-615-369-6463
www.thehealingnet.org

Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS)
P.O. Box 370466
Denver, CO 80237
www.lacnets.org

Neuroendocrine Cancer Awareness Network (NCAN)
3074 Brookchase Boulevard
Fort Mill, SC 29707
1-866-850-9555
help@netcancerawareness.org
www.netcancerawareness.org

Northern California CarciNET Community (NorCal CarciNET)
946 North Ripon Road
Ripon, CA 95366
www.norcalcarcinet.org

Provided for informational purposes only. This is not intended to be a recommendation or endorsement of any organization.

Novartis Patient Support™

Novartis Patient Support provides dedicated, ongoing help and resources, starting when you sign up.

Available support offered by Novartis Patient Support includes:

Live Support | **Insurance Support** | **Savings Support**

A dedicated team is just a phone call away

Our Novartis Patient Support Team can help provide information on benefits verification and prior authorizations. They are available to help you, your health care provider, and your care team.

Co-pay savings start when you sign up

We understand that paying for treatment, including co-pays, can sometimes be a burden. A co-pay is the amount of money your insurance company asks you to pay for an appointment, procedure, or medication.

Novartis Patient Support Co-Pay Savings is available to patients with private insurance (or insurance provided by an employer or purchased individually) who meet specific eligibility criteria. Once you sign up for Novartis Patient Support, you will be considered for co-pay savings.

$25 CO-PAY*

If you have private insurance, you may pay as little as $25 per dose.*

To start the process, check with your health care provider or care team to make sure your Enrollment Form is completed, signed, and submitted.

*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare or any other federal or state program. Offer subject to a maximum benefit per course of treatment. See complete Terms and Conditions in the Enrollment Forms for details.

Additional financial support may be available for patients without private insurance

If you don't have private or government insurance (for example, Medicare or Medicaid insurance), you may be eligible for other savings support options. For more information call 1-888-NOW-NOVA (1-888-669-6682).

For more information about Novartis Patient Support, call 1-888-NOW-NOVA (1-888-669-6682)

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

Novartis Patient Support (continued)

Enrolling in Novartis Patient Support

1 Ask your health care provider or care team about getting started with Novartis Patient Support

Staying on track with treatment is easier with reliable support. Novartis Patient Support helps you get started and stay on treatment.

2 Work with your health care provider or care team to complete and sign the Enrollment Form

Fill out all required sections of the Enrollment Form with your health care provider or care team. Then, sign the form to authorize your enrollment in Novartis Patient Support.

3 Connect with your Novartis Patient Support Team

A dedicated Novartis Patient Support Team member will connect with you and your health care provider or care team to confirm sign up and provide additional information about options that match your treatment plan.

For more information about Novartis Patient Support, call 1-888-NOW-NOVA (1-888-669-6682)

Summary of Important Information

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop your treatment. You should always follow your health care provider's instructions. Safety considerations include:

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation, which can contribute to your long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer. The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your health care provider.
- **Bone marrow problems:** Treatment with LUTATHERA increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts. You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia). Speak with your health care provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. Your health care provider may need to adjust or stop your treatment accordingly.
- **Secondary bone marrow and blood cancers:** Other serious conditions that you may develop as a direct result of treatment with LUTATHERA include blood and bone marrow disorders known as secondary myelodysplastic syndrome and cancer known as acute leukemia. Your health care provider will routinely check your blood cell counts and tell you if they are too low or too high.
- **Kidney problems:** Treatment with LUTATHERA will expose your kidneys to radiation and may impair their ability to work as normal. You may be at an increased risk for kidney problems after LUTATHERA treatment if you already have kidney impairment before treatment. In some cases, patients have experienced kidney failure after treatment with LUTATHERA. Your health care provider will provide you with an amino acid solution before, during, and after LUTATHERA to help protect your kidneys. You should stay well hydrated before, on the day of, and on the day after your treatment. You should urinate frequently before, on the day of, and on the day after administration of LUTATHERA. Your doctor will monitor your kidney function and may withhold, reduce, or stop your LUTATHERA treatment accordingly.
- **Liver problems:** In clinical studies of LUTATHERA, less than 1% of patients were reported to have tumor bleeding (hemorrhage), swelling (edema), or tissue damage (necrosis) to the liver. If you have tumors in your liver, you may be more likely to experience these side effects. Tell your health care provider right away if you have any of these signs and symptoms of liver problems: yellowing of the skin or the whites of the eyes (jaundice), unusual darkening of the urine, unusual tiredness, right upper stomach area (abdomen) pain, confusion, and/or swelling of the stomach area (abdomen). Your health care provider will monitor your liver using blood tests and may need to withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see additional Important Safety Information throughout and the Summary of Important Information on pages 22 and 23.

VISIT LUTATHERA.COM

What are some important things to know about the safety of LUTATHERA? (continued)

- **Allergic reactions:** Allergic reactions have occurred in people who were treated with LUTATHERA. Notify your health care provider if you develop symptoms of an allergic reaction. Seek emergency help right away for any serious allergic reactions. Symptoms may include trouble breathing or swallowing; raised bumps (hives); rash or itching; and swelling of the face, lips, tongue, throat, or arms.
- **Hormonal gland problems (carcinoid crisis):** During your treatment you may experience certain symptoms that are related to hormones released from your cancer. These symptoms may include flushing, diarrhea, difficulty breathing (bronchospasm), and low blood pressure (hypotension), and may occur during or within the 24 hours after your first LUTATHERA treatment. Your health care provider will monitor you closely. Speak with your health care provider if you experience any of these signs or symptoms.
- **Pregnancy warning:** Tell your health care provider if you are pregnant. LUTATHERA can harm your unborn baby. Females should use an effective method of birth control during treatment and for 7 months after the last dose of LUTATHERA. Males with female partners should use an effective method of birth control during treatment with LUTATHERA and for 4 months after the last dose.
- **Breastfeeding warning:** You should not breastfeed during treatment with LUTATHERA and for 2.5 months after your last dose of LUTATHERA.
- **Fertility problems:** Treatment with LUTATHERA may cause infertility. This is because radiation absorbed by your testes or ovaries over the treatment period falls within the range of exposure in which temporary or permanent infertility may occur.

What are the most common side effects of LUTATHERA?

The most common and most serious side effects of LUTATHERA include decreased blood cell counts, increased liver enzymes, vomiting, nausea, increased blood glucose, and decreased blood potassium levels.

Talk to your doctor if you experience any of these side effects. There are other possible side effects of LUTATHERA. For more information and to learn more about LUTATHERA, talk to your doctor or health care provider.

What other medicines may interact with LUTATHERA?

Tell your health care provider if you are taking any other medications. Somatostatin analogs and glucocorticoids may affect how your LUTATHERA treatment works. You should stop taking your long-acting somatostatin analog at least 4 weeks before LUTATHERA treatment. You may continue taking short-acting somatostatin analogs up to 24 hours before your LUTATHERA treatment. Avoid repeated high doses of glucocorticoids during treatment with LUTATHERA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

A GUIDE TO YOUR
Treatment With LUTATHERA

APPOINTMENTS	INFORMATION	QUESTIONS

Have regular conversations with your health care professional while on LUTATHERA

For more information about LUTATHERA, visit:

Facebook.com/LUTATHERA

VISIT LUTATHERA.COM

NOVARTIS

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

9/23

308396